MedPacto

At a glance

MedPacto filed 29 disclosures in the last 12 months.

Revenue for 2025 was ₩3.9B. It made an operating loss of ₩14B. Debt was 6% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩2.4B and operating loss of ₩7.8B.

The 2025 annual report lists 54 employees with an average tenure of 3.5 years and average pay of ₩57.3M, #1306 of 2,191 listed companies by average pay. Its 8 directors and auditors were paid ₩96M each on average. It paid no cash dividend for 2025. (주)테라젠이텍스 and related parties held 19.61% at year end.

From the 2025 annual report

Staff: 54 (28 men, 26 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩3.1B. Directors and auditors: 8, paid ₩769M in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)테라젠이텍스 holds 14.39%; with 8 related parties the group holds 19.61% of common shares at year end (from 27.26% at the start of the year).

Auditor: 신한회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary